Platelet Function During ECMO (Extra Corporeal Membrane Oxygenation)

NCT00748878 | Completed

• 1 other identifier: 28645
• Study Type: observational
• Target: 5
• Locations: 1 country
• Sites: 1

Brief Summary

Platelet transfusions are routinely administered during neonatal ECMO, with an average of 1.3 platelet transfusions per day being administered while a patient is undergoing ECMO treatment. The cause of thrombocytopenia during ECMO largely involves platelet adherence to the oxygenator membrane. Platelet transfusions carry risks such as infections with bacteria or yeast, and development or worsening of pulmonary hypertension. It is likely that if fewer platelet transfusions can be administered during the ECMO run, the cumulative adverse effects of platelet transfusions would diminish and patient outcomes improve. In order to better understand platelet function during ECMO, the investigators plan to serially determine the circulating platelet mass, plasma platelet factor 4 concentration, megakaryocyte mass (estimated by plasma thrombopoietin concentration), and platelet function as quantified by PFA100. Any patient on ECMO will be eligible for this pilot study of 5 patients. By understanding changes in platelet function, we hope to design a future study that may modify the frequency or need for platelet transfusions during ECMO.

Conditions

Platelet Function; Thrombocytopenia

Keywords

To better understand platelet function during ECMO

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Any patient on ECMO will be eligible for study.

You may qualify if:

• Any patient on ECMO will be eligible for study.

Sponsors & Collaborators

• University of Utah: lead

Study Sites (1)

Primary Children's Medical Center

Salt Lake City, Utah, 84113, United States

Location

MeSH Terms

Conditions

Thrombocytopenia

Condition Hierarchy (Ancestors)

Blood Platelet Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Cytopenia

Study Officials

• Donald .Null, M.D.

  University of Utah

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: September 8, 2008
• First Posted: September 9, 2008
• Study Start: June 1, 2008
• Primary Completion: June 1, 2012
• Study Completion: June 1, 2013
• Last Updated: October 16, 2013

Record last verified: 2013-10

Locations

US (1)